| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
As a short N-terminal fragment, it does not directly bind to classical AT1 or AT2 receptors with high affinity. However, it is derived from angiotensin I (which is converted by ACE to the active vasoconstrictor angiotensin II) and can be used to study ACE enzyme activity.
|
|---|---|
| ln Vitro |
Angiotensin II is a powerful vasoconstrictor and a naturally occurring octapeptide hormone that is a part of the renin-angiotensin-aldosterone system (RAAS). Angiotensin II plays critical functions in the regulation of blood pressure, thirst perception, the baroreceptor reflex, renal blood flow and glomerular filtration rate, as well as the equilibrium of electrolytes and free water in the cardiovascular, neurological, and renal systems[2].
Angiotensin I is considered a prohormone with limited biological activity, requiring conversion to angiotensin II by ACE to become active. As a fragment, Angiotensin I/II (1-6) itself does not elicit significant receptor-mediated signaling in standard cell assays. |
| ln Vivo |
As a peptide fragment, it does not possess intrinsic vasoactive properties in vivo. Instead, it serves as a substrate or metabolite in the RAAS pathway. In vivo studies focus on its conversion to longer peptides or its role as an ACE substrate rather than direct physiological effects.
|
| Enzyme Assay |
Enzyme activity assays utilize angiotensin I-converting enzyme (ACE) and measure the conversion of angiotensin I to angiotensin II via HPLC or immunoassay. Non-radioactive methods based on competitive ELISA have been developed for angiotensin receptor binding studies using rat liver membranes and FITC-labeled angiotensin II.
|
| Cell Assay |
Angiotensin I/II (1-6) is not typically used in direct cell-based functional assays as it lacks intrinsic activity. It may be added to cells expressing ACE to study enzymatic conversion or as a control in peptide stability and metabolism studies.
|
| Animal Protocol |
No standardized animal model exists for this fragment alone. It is often administered as part of pharmacokinetic studies to track peptide metabolism or as a precursor in RAAS pathway studies, with blood samples analyzed for conversion products via LC-MS/MS.
|
| ADME/Pharmacokinetics |
As a peptide fragment, its pharmacokinetic profile is characterized by rapid degradation by peptidases in plasma and tissues. Its half-life is short, similar to other small peptides, and it is metabolized primarily via hydrolysis.
|
| Toxicity/Toxicokinetics |
Since it is a naturally occurring peptide fragment with low biological activity, it shows low toxicity in standard research settings. No significant adverse effects are reported when used as a research reagent. Standard safety precautions for peptide handling apply.
|
| References | |
| Additional Infomation |
This compound is an N-terminal fragment of the decapeptide angiotensin I and is often used as a reference standard or control in RAAS-related research. It is not intended for therapeutic use and is not approved by the FDA. It is strictly a research-grade biochemical tool.
|
| Molecular Formula |
C38H56F3N11O12
|
|---|---|
| Molecular Weight |
915.91
|
| Related CAS # |
Angiotensin I/II (1-6);47896-63-9
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~100 mg/mL (~109.18 mM)
DMSO :≥ 100 mg/mL (~109.18 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0918 mL | 5.4591 mL | 10.9181 mL | |
| 5 mM | 0.2184 mL | 1.0918 mL | 2.1836 mL | |
| 10 mM | 0.1092 mL | 0.5459 mL | 1.0918 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
